ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
nCOV19-antibody.pdf (6.07 MB)

In silico Antibody Mutagenesis for Optimizing its Binding to the Spike Protein of SARS-CoV-2

preprint
submitted on 17.09.2020 and posted on 18.09.2020 by Binquan Luan, Tien Huynh

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic and there are currently no FDA approved medicines for treatment or prevention. Inspired by promising outcomes for convalescent plasma treatment, developing antibody drugs (biologics) to block SARS-CoV-2 infection has been the focus of drug discovery, along with tremendous efforts in repurposing small-molecule drugs. In the last several months, experimentally, many human neutralizing monoclonal antibodies (mAbs) were successfully extracted from plasma of recovered COVID-19 patients. Currently, several mAbs targeting the SARS-CoV-2's spike protein (Spro) are in clinical trials. With known atomic structures of mAb-Spro complex, it becomes possible to in silico investigate the molecular mechanism of mAb's binding with Spro and design more potent mAbs through protein mutagenesis studies, complementary to existing experimental efforts. Leveraging superb computing power nowadays, we propose a fully automated in silico protocol for quickly identifying possible mutations in a mAb (e.g.~CB6) to enhance its binding affinity with Spro for the design of more efficacious therapeutic mAbs.

History

Email Address of Submitting Author

bluan@us.ibm.com

Institution

IBM T J Watson Research

Country

USA

ORCID For Submitting Author

0000-0002-9414-5379

Declaration of Conflict of Interest

none

Exports

Logo branding

Exports